Format
Sort by

Send to

Choose Destination

Selected items

Items: 20

1.

Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE 3rd.

N Engl J Med. 2012 Oct 18;367(16):1508-18. doi: 10.1056/NEJMoa1201964.

2.

Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.

Chang KC, Yew WW.

Respirology. 2013 Jan;18(1):8-21. doi: 10.1111/j.1440-1843.2012.02257.x. Review.

3.

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.

Caminero JA, Sotgiu G, Zumla A, Migliori GB.

Lancet Infect Dis. 2010 Sep;10(9):621-9. doi: 10.1016/S1473-3099(10)70139-0. Review.

PMID:
20797644
4.

Microevolution of extensively drug-resistant tuberculosis in Russia.

Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, Harris SR, Bentley SD, Parkhill J, Nejentsev S, Hoffner SE, Horstmann RD, Brown T, Drobniewski F.

Genome Res. 2012 Apr;22(4):735-45. doi: 10.1101/gr.128678.111.

5.

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE.

Chest. 2009 Aug;136(2):420-5. doi: 10.1378/chest.08-2427.

PMID:
19349380
6.

Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.

Streicher EM, Müller B, Chihota V, Mlambo C, Tait M, Pillay M, Trollip A, Hoek KG, Sirgel FA, Gey van Pittius NC, van Helden PD, Victor TC, Warren RM.

Infect Genet Evol. 2012 Jun;12(4):686-94. doi: 10.1016/j.meegid.2011.07.019. Review.

PMID:
21839855
7.

Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis.

Cheepsattayakorn A, Cheepsattayakorn R.

Recent Pat Antiinfect Drug Discov. 2012 Aug;7(2):141-56. Review.

PMID:
22670838
8.

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G.

Lancet. 2006 Nov 4;368(9547):1575-80.

PMID:
17084757
10.

Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.

Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS.

Science. 2009 Feb 27;323(5918):1215-8. doi: 10.1126/science.1167498.

11.

Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis.

Walter ND, Strong M, Belknap R, Ordway DJ, Daley CL, Chan ED.

Respirology. 2012 Jul;17(5):772-91. doi: 10.1111/j.1440-1843.2012.02176.x. Review.

12.

Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.

Centers for Disease Control and Prevention (CDC)..

MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43.

13.

Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies.

Prasad R.

Lung India. 2012 Apr;29(2):154-9. doi: 10.4103/0970-2113.95321.

14.

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J.

Lancet. 2010 May 22;375(9728):1830-43. doi: 10.1016/S0140-6736(10)60410-2.

PMID:
20488523
15.

Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.

Porwal C, Kaushik A, Makkar N, Banavaliker JN, Hanif M, Singla R, Bhatnagar AK, Behera D, Pande JN, Singh UB.

PLoS One. 2013;8(2):e55299. doi: 10.1371/journal.pone.0055299.

16.

Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory.

Barnard M, Warren R, Gey Van Pittius N, van Helden P, Bosman M, Streicher E, Coetzee G, O'Brien R.

Am J Respir Crit Care Med. 2012 Dec 15;186(12):1298-305. doi: 10.1164/rccm.201205-0960OC.

PMID:
23087027
17.

Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa.

Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, Mathema B, Shashkina E, Rothenberg R, Moll AP, Friedland G, Sturm AW, Shah NS.

J Infect Dis. 2013 Jan 1;207(1):9-17. doi: 10.1093/infdis/jis631.

18.

Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China.

Yuan X, Zhang T, Kawakami K, Zhu J, Li H, Lei J, Tu S.

J Clin Microbiol. 2012 Jul;50(7):2404-13. doi: 10.1128/JCM.06860-11.

19.

Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine.

Abbate E, Vescovo M, Natiello M, Cufré M, García A, Gonzalez Montaner P, Ambroggi M, Ritacco V, van Soolingen D.

J Antimicrob Chemother. 2012 Feb;67(2):473-7. doi: 10.1093/jac/dkr500.

PMID:
22134348
20.

Linezolid for extensively drug-resistant tuberculosis.

Cattaneo D, Orlando G, Cordier L.

N Engl J Med. 2013 Jan 17;368(3):291. doi: 10.1056/NEJMc1214183#SA3. No abstract available.

PMID:
23323919
Items per page

Supplemental Content

Support Center